Tramadol disposition in the very young:: an attempt to assess in vivo cytochrome P-450 2D6 activity

被引:76
作者
Allegaert, K
Anderson, BJ
Verbesselt, R
Debeer, A
de Hoon, J
Devlieger, H
Van den Anker, JN
Tibboel, D
机构
[1] Univ Hosp Gasthuisberg, Dept Paediat, Neonatal Intens Care Unit, B-3000 Louvain, Belgium
[2] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat Surg, Rotterdam, Netherlands
[3] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat, Rotterdam, Netherlands
[4] Univ Auckland, Dept Anaesthesiol, Auckland 1, New Zealand
[5] Univ Hosp Gasthuisberg, Ctr Clin Phrmacol, B-3000 Louvain, Belgium
[6] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA
[7] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA
[8] George Washington Univ, Sch Med & Hlth Sci, Dept Pharmacol, Washington, DC 20052 USA
[9] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol, Washington, DC 20052 USA
关键词
analgesics opioid; tramadol; drug; age factors; pharmacokinetics; maturation; CYP2D6; activity;
D O I
10.1093/bja/aei170
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Tramadol is potentially a very useful pain relief medication in neonates and infants. It is primarily metabolized into O-demethyl tramadol (M1) by CYP2D6. Data concerning tramadol disposition and CYP2D6 activity in young infants are not available. Methods. A population pharmacokinetic analysis of tramadol and M1 time-concentration profiles was undertaken using non-linear mixed-effects models (NONMEM), based on newly collected data on tramadol and M1 time-concentration profiles in neonates and young infants (n=20) and published studies on intravenous tramadol in children and adults. M1 formation served as a surrogate for CYP2D6 activity. Results. Tramadol clearance was described using a two-compartment linear model with zero-order input and first-order elimination. Clearance increased from 25 weeks post-conception age (PCA) (5.52 litre h(-1) [70 kg](-1)) to reach 84% of the mature value by 44 weeks PCA (standardized to a 70 kg adult using allometric '1/4 power' models). The central volume of distribution decreased from 25 weeks PCA (256 litre [70 kg](-1)) to reach 120% of its mature value by 87 weeks PCA. Formation clearance to M1 contributed 43% of tramadol clearance, but had no relationship with PCA. There was a weak non-linear relationship between PCA and M1 metabolite clearance. Conclusions. Maturational clearance of tramadol is almost complete by 44 weeks PCA. A target concentration of 300 mu g litre(-1) is achieved after a bolus of tramadol hydrochloride 1 mg kg(-1) and can be maintained by infusion of tramadol hydrochloride 0.09 mg kg(-1) h(-1) at 25 weeks PCA, 0.14 mg kg(-1) h(-1) at 30 weeks PCA, 0.17 mg kg(-1) h(-1) at 35 weeks PCA, 0.18 mg kg(-1) h(-1) at 40 weeks, 0.19 mg kg(-1) h(-1) at 50 weeks PCA to 1 yr, 0.18 mg kg(-1) h(-1) at 3 yr and 0.12 mg kg(-1) h(-1) in adulthood. CYP2D6 activity was observed as early as 25 weeks PCA, but the impact of CYP2D6 polymorphism on the variability in pharmacokinetics, metabolism and pharmacodynamics of tramadol remains to be established.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 31 条
  • [1] Concordance between tramadol and dextromethorphan parent/metabolite ratios: The influence of CYP2D6 and non-CYP2D6 pathways on biotransformation
    Abdel-Rahman, SM
    Leeder, JS
    Wilson, JT
    Gaedigk, A
    Gotschall, RR
    Medve, R
    Liao, S
    Spielberg, SP
    Kearns, GL
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (01) : 24 - 29
  • [2] Tramadol concentrations in blood and in cerebrospinal fluid in a neonate
    Allegaert, K
    de Hoon, J
    Verbesselt, R
    Devlieger, H
    Tibboel, D
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (12) : 911 - 913
  • [3] Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed
    Allegaert, K
    Tibboel, D
    Naulaers, G
    Tison, D
    De Jonge, A
    Van Dijk, M
    Vanhole, C
    Devlieger, H
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) : 87 - 90
  • [4] Scaling for size: some implications for paediatric anaesthesia dosing
    Anderson, BJ
    Meakin, GH
    [J]. PAEDIATRIC ANAESTHESIA, 2002, 12 (03): : 205 - 219
  • [5] Beal SL, 1999, NONMEM USERS GUIDE
  • [6] A rapid and simple CYP2D6 genotyping assay - Case study with the analgetic tramadol
    Borlak, J
    Hermann, R
    Erb, K
    Thum, T
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (11): : 1439 - 1443
  • [7] High-performance liquid chromatographic assay for simultaneous determination of tramadol and its active metabolite in human plasma.: Application to pharmacokinetic studies
    Campanero, MA
    Calahorra, B
    García-Quetglás, E
    Escolar, M
    Honorato, J
    [J]. CHROMATOGRAPHIA, 1998, 48 (7-8) : 555 - 560
  • [8] Campanero MA, 1999, CHIRALITY, V11, P272, DOI 10.1002/(SICI)1520-636X(1999)11:4<272::AID-CHIR3>3.0.CO
  • [9] 2-I
  • [10] Conner, 1983, ECOLOGICAL IMPLICATI, P48, DOI 10.1017/CBO9780511608551